annual cash & cash equivalents:
$10.35B-$1.12B(-9.75%)Summary
- As of today (August 5, 2025), BMY annual cash & cash equivalents is $10.35 billion, with the most recent change of -$1.12 billion (-9.75%) on December 31, 2024.
- During the last 3 years, BMY annual cash & cash equivalents has fallen by -$3.63 billion (-25.99%).
- BMY annual cash & cash equivalents is now -28.87% below its all-time high of $14.55 billion, reached on December 31, 2020.
Performance
BMY Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$12.60B+$1.72B(+15.85%)Summary
- As of today (August 5, 2025), BMY quarterly cash & cash equivalents is $12.60 billion, with the most recent change of +$1.72 billion (+15.85%) on June 30, 2025.
- Over the past year, BMY quarterly cash & cash equivalents has increased by +$6.31 billion (+100.21%).
- BMY quarterly cash & cash equivalents is now -58.68% below its all-time high of $30.49 billion, reached on September 30, 2019.
Performance
BMY quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
BMY Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -9.8% | +100.2% |
| 3 y3 years | -26.0% | +17.2% |
| 5 y5 years | -16.2% | -36.8% |
BMY Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -26.0% | +13.4% | at high | +100.2% |
| 5 y | 5-year | -28.9% | +13.4% | -36.8% | +100.2% |
| alltime | all time | -28.9% | +1928.6% | -58.7% | +2370.4% |
BMY Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $12.60B(+15.9%) |
| Mar 2025 | - | $10.88B(+5.1%) |
| Dec 2024 | $10.35B(-9.8%) | $10.35B(+31.1%) |
| Sep 2024 | - | $7.89B(+25.4%) |
| Jun 2024 | - | $6.29B(-32.6%) |
| Mar 2024 | - | $9.33B(-18.6%) |
| Dec 2023 | $11.46B(+25.7%) | $11.46B(+52.6%) |
| Sep 2023 | - | $7.51B(-10.2%) |
| Jun 2023 | - | $8.37B(-6.9%) |
| Mar 2023 | - | $8.99B(-1.4%) |
| Dec 2022 | $9.12B(-34.7%) | $9.12B(+18.0%) |
| Sep 2022 | - | $7.73B(-28.1%) |
| Jun 2022 | - | $10.75B(-13.1%) |
| Mar 2022 | - | $12.37B(-11.5%) |
| Dec 2021 | $13.98B(-3.9%) | $13.98B(+3.2%) |
| Sep 2021 | - | $13.54B(+22.8%) |
| Jun 2021 | - | $11.02B(+0.4%) |
| Mar 2021 | - | $10.98B(-24.5%) |
| Dec 2020 | $14.55B(+17.8%) | $14.55B(-25.2%) |
| Sep 2020 | - | $19.43B(-2.5%) |
| Jun 2020 | - | $19.93B(+26.0%) |
| Mar 2020 | - | $15.82B(+28.1%) |
| Dec 2019 | $12.35B(+78.6%) | $12.35B(-59.5%) |
| Sep 2019 | - | $30.49B(+7.3%) |
| Jun 2019 | - | $28.40B(+287.2%) |
| Mar 2019 | - | $7.33B(+6.1%) |
| Dec 2018 | $6.91B(+27.5%) | $6.91B(+27.8%) |
| Sep 2018 | - | $5.41B(+8.2%) |
| Jun 2018 | - | $5.00B(-6.4%) |
| Mar 2018 | - | $5.34B(-1.5%) |
| Dec 2017 | $5.42B(+27.9%) | $5.42B(+16.7%) |
| Sep 2017 | - | $4.64B(+33.8%) |
| Jun 2017 | - | $3.47B(-11.3%) |
| Mar 2017 | - | $3.91B(-7.7%) |
| Dec 2016 | $4.24B(+77.7%) | $4.24B(+23.5%) |
| Sep 2016 | - | $3.43B(+17.0%) |
| Jun 2016 | - | $2.93B(+11.0%) |
| Mar 2016 | - | $2.64B(+10.9%) |
| Dec 2015 | $2.38B(-57.2%) | $2.38B(-40.0%) |
| Sep 2015 | - | $3.98B(-5.3%) |
| Jun 2015 | - | $4.20B(-33.3%) |
| Mar 2015 | - | $6.29B(+13.0%) |
| Dec 2014 | $5.57B(+55.4%) | $5.57B(+14.8%) |
| Sep 2014 | - | $4.85B(+13.3%) |
| Jun 2014 | - | $4.28B(-18.0%) |
| Mar 2014 | - | $5.22B(+45.7%) |
| Dec 2013 | $3.59B(+116.5%) | $3.59B(+102.5%) |
| Sep 2013 | - | $1.77B(-2.7%) |
| Jun 2013 | - | $1.82B(+34.4%) |
| Mar 2013 | - | $1.35B(-18.2%) |
| Dec 2012 | $1.66B(-71.3%) | $1.66B(+10.2%) |
| Sep 2012 | - | $1.50B(-46.3%) |
| Jun 2012 | - | $2.80B(+21.4%) |
| Mar 2012 | - | $2.31B(-60.1%) |
| Dec 2011 | $5.78B(+14.8%) | $5.78B(+29.2%) |
| Sep 2011 | - | $4.47B(+22.0%) |
| Jun 2011 | - | $3.67B(+7.6%) |
| Mar 2011 | - | $3.40B(-32.3%) |
| Dec 2010 | $5.03B(-34.5%) | $5.03B(-15.0%) |
| Jun 2010 | - | $5.92B(+15.2%) |
| Mar 2010 | - | $5.13B(-33.2%) |
| Dec 2009 | $7.68B(-3.7%) | $7.68B(+20.7%) |
| Sep 2009 | - | $6.37B(-15.2%) |
| Jun 2009 | - | $7.51B(-4.1%) |
| Mar 2009 | - | $7.83B(-1.8%) |
| Dec 2008 | $7.98B(+342.9%) | $7.98B(+11.2%) |
| Sep 2008 | - | $7.17B(+77.2%) |
| Jun 2008 | - | $4.05B(+65.7%) |
| Mar 2008 | - | $2.44B(+35.6%) |
| Dec 2007 | $1.80B | $1.80B(+9.4%) |
| Sep 2007 | - | $1.65B(-30.8%) |
| Jun 2007 | - | $2.38B(+7.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2007 | - | $2.21B(+9.7%) |
| Dec 2006 | $2.02B(-33.8%) | $2.02B(-28.8%) |
| Sep 2006 | - | $2.83B(+8.9%) |
| Jun 2006 | - | $2.60B(+5.0%) |
| Mar 2006 | - | $2.48B(-18.8%) |
| Dec 2005 | $3.05B(-17.1%) | $3.05B(+43.3%) |
| Sep 2005 | - | $2.13B(+18.4%) |
| Jun 2005 | - | $1.80B(-45.7%) |
| Mar 2005 | - | $3.31B(-10.0%) |
| Dec 2004 | $3.68B(+44.4%) | $3.68B(+8.8%) |
| Sep 2004 | - | $3.38B(+7.1%) |
| Jun 2004 | - | $3.16B(+3.0%) |
| Mar 2004 | - | $3.06B(+20.2%) |
| Dec 2003 | $2.55B(+7.7%) | $2.55B(-48.5%) |
| Sep 2003 | - | $4.95B(+15.0%) |
| Jun 2003 | - | $4.31B(-0.5%) |
| Mar 2003 | - | $4.33B(+82.8%) |
| Dec 2002 | $2.37B(-57.0%) | $2.37B(-33.5%) |
| Sep 2002 | - | $3.56B(+0.4%) |
| Jun 2002 | - | $3.55B(+4.9%) |
| Mar 2002 | - | $3.38B(-38.5%) |
| Dec 2001 | $5.50B(+72.8%) | $5.50B(+96.4%) |
| Sep 2001 | - | $2.80B(-4.9%) |
| Jun 2001 | - | $2.94B(+11.8%) |
| Mar 2001 | - | $2.63B(-17.2%) |
| Dec 2000 | $3.18B(+17.0%) | $3.18B(+15.3%) |
| Sep 2000 | - | $2.76B(+24.2%) |
| Jun 2000 | - | $2.22B(-10.0%) |
| Mar 2000 | - | $2.47B(-9.3%) |
| Dec 1999 | $2.72B(+21.2%) | $2.72B(+10.8%) |
| Sep 1999 | - | $2.46B(+18.0%) |
| Jun 1999 | - | $2.08B(+3.9%) |
| Mar 1999 | - | $2.00B(-10.7%) |
| Dec 1998 | $2.24B(+54.1%) | $2.24B(+46.6%) |
| Sep 1998 | - | $1.53B(+52.3%) |
| Jun 1998 | - | $1.00B(-35.8%) |
| Mar 1998 | - | $1.56B(+7.5%) |
| Dec 1997 | $1.46B(-13.4%) | $1.46B(-12.5%) |
| Sep 1997 | - | $1.66B(+11.5%) |
| Jun 1997 | - | $1.49B(-17.4%) |
| Mar 1997 | - | $1.81B(+7.5%) |
| Dec 1996 | $1.68B(+2.2%) | $1.68B(+22.9%) |
| Sep 1996 | - | $1.37B(+21.7%) |
| Jun 1996 | - | $1.12B(-13.9%) |
| Mar 1996 | - | $1.30B(-20.7%) |
| Dec 1995 | $1.65B(+0.2%) | $1.65B(-1.7%) |
| Sep 1995 | - | $1.67B(-2.6%) |
| Jun 1995 | - | $1.72B(-2.7%) |
| Mar 1995 | - | $1.77B(+7.6%) |
| Dec 1994 | $1.64B(-32.2%) | $1.64B(-10.9%) |
| Sep 1994 | - | $1.84B(-16.2%) |
| Jun 1994 | - | $2.20B(-12.8%) |
| Mar 1994 | - | $2.52B(+4.2%) |
| Dec 1993 | $2.42B(+13.3%) | $2.42B(+4.0%) |
| Sep 1993 | - | $2.33B(+8.0%) |
| Jun 1993 | - | $2.15B(+32.9%) |
| Mar 1993 | - | $1.62B(-24.1%) |
| Dec 1992 | $2.14B(+48.9%) | $2.14B(+121.0%) |
| Sep 1992 | - | $967.00M(+18.8%) |
| Jun 1992 | - | $814.00M(-30.5%) |
| Mar 1992 | - | $1.17B(-18.3%) |
| Dec 1991 | $1.44B(+140.8%) | $1.44B(+10.4%) |
| Sep 1991 | - | $1.30B(+19.4%) |
| Jun 1991 | - | $1.09B(+79.1%) |
| Mar 1991 | - | $608.00M(+2.0%) |
| Dec 1990 | $596.00M(+16.9%) | $596.00M(-48.6%) |
| Sep 1990 | - | $1.16B(-5.0%) |
| Jun 1990 | - | $1.22B(+30.7%) |
| Mar 1990 | - | $934.00M(+83.1%) |
| Dec 1989 | $510.00M(-79.7%) | $510.00M(-79.7%) |
| Dec 1988 | $2.51B(+7.0%) | $2.51B(+7.0%) |
| Dec 1987 | $2.35B | $2.35B |
FAQ
- What is Bristol-Myers Squibb Company annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Bristol-Myers Squibb Company?
- What is Bristol-Myers Squibb Company annual cash & cash equivalents year-on-year change?
- What is Bristol-Myers Squibb Company quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Bristol-Myers Squibb Company?
- What is Bristol-Myers Squibb Company quarterly cash & cash equivalents year-on-year change?
What is Bristol-Myers Squibb Company annual cash & cash equivalents?
The current annual cash & cash equivalents of BMY is $10.35B
What is the all time high annual cash & cash equivalents for Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company all-time high annual cash & cash equivalents is $14.55B
What is Bristol-Myers Squibb Company annual cash & cash equivalents year-on-year change?
Over the past year, BMY annual cash & cash equivalents has changed by -$1.12B (-9.75%)
What is Bristol-Myers Squibb Company quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of BMY is $12.60B
What is the all time high quarterly cash & cash equivalents for Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company all-time high quarterly cash & cash equivalents is $30.49B
What is Bristol-Myers Squibb Company quarterly cash & cash equivalents year-on-year change?
Over the past year, BMY quarterly cash & cash equivalents has changed by +$6.31B (+100.21%)